Viridian Therapeutics (VRDN) closed at $22.37 on October 23, 2026, down 2.0% from the previous close, on volume of 1,022,427 shares (30-day average 1,969,141).
Data as of October 23, 2026.
23-Oct-2026
Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
Business Wire (Tue, 20-Oct 4:00 PM ET)
Business Wire (Thu, 6-Aug 7:01 AM ET)
Market Chameleon (Thu, 7-May 4:17 AM ET)
Viridian Therapeutics Prepares for TED Launch with Positive Clinical Data and $762M Cash Reserve
Market Chameleon (Tue, 5-May 4:02 AM ET)
Viridian’s Accelerating Pipeline and $875M Cash Position Set Up for Key 2026 Milestones
Market Chameleon (Thu, 26-Feb 2:39 AM ET)
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Viridian Therapeutics trades on the NASDAQ stock market under the symbol VRDN.
As of October 23, 2026, VRDN stock price declined to $22.37 with 1,022,427 million shares trading.
VRDN has a beta of -0.34, meaning it tends to be less sensitive to market movements. VRDN has a correlation of 0.00 to the broad based SPY ETF.
VRDN has a market cap of $2.53 billion. This is considered a Mid Cap stock.
Last quarter Viridian Therapeutics reported $233,000 in Revenue and -$1.05 earnings per share. This beat revenue expectation by $211,000 and missed earnings estimates by -$.03.
In the last 3 years, VRDN traded as high as $34.29 and as low as $9.90.
The top ETF exchange traded funds that VRDN belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.
VRDN has underperformed the market in the last year with a return of +1.4%, while SPY returned +14.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in VRDN shares. However, VRDN has outperformed the market in the last 3 month and 2 week periods, returning +16.1% and +19.9%, while SPY returned +3.2% and -2.4%, respectively. This indicates VRDN has been having a stronger performance recently.
VRDN support price is $22.00 and resistance is $23.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRDN shares will trade within this expected range on the day.
